A new precision medicine-driven digital infrastructure, collaborative in nature and inclusive of various research centers, new biomarkers, oncology detection strategies, immunotherapies and system biology toolsets—needs to be synchronized and packaged for rapid clinical investigator consumption.
In the digital era the 5 ‘P’s’ of healthcare will predominate—preventative, predictive, participatory, personalized and pertinent, reports Giorgio V. Scaglioti, MD, PhD. Dr. Scaglioti reports on these needs during his presentation titled “Changing Translational Research in NSCLC: Future Prospects.” Follow the link below to Onclive to read the rest of this interesting article.
Giogio V. Scaglioti, MD, PhD
Chief of the Medical Oncology Division at the S. Luigi Hospital, Orbassano (Torino), Head of the Department of Oncology at University of Torino, Italy
Dr. Scagliotti is currently Professor of Oncology at the University of Torino. Dr. Scagliotti earned his medical degree and completed the postgraduate training in Respiratory Medicine, Internal Medicine, and Medical Oncology at the University of Torino. He is currently chief of the Medical Oncology Division at the S. Luigi Hospital, Orbassano (Torino), Head of the Department of Oncology at University of Torino.
Dr. Scagliotti is a member of several scientific societies, including the Italian Society of Respiratory Medicine, the European Respiratory Society, the American Society of Clinical Oncology, and the International Association for the Study of Lung Cancer. From 2003-07, he was Executive Board Member of the International Association for the Study of Lung Cancer. He is Associate Editor for Journal of Thoracic Oncology and International Editor for Clinical Lung Cancer. He is the author or co-author of more than 280 publications in peer-reviewed journals and he is the International Editor of the 4th Edition of “Lung Cancer : Principles and practice” and co-editor of the IASLC textbook of multidisciplinary approach to thoracic Oncology.Source: OncLive